Search

Your search keyword '"Schubert, Erin K."' showing total 154 results
Start Over Author "Schubert, Erin K."
154 results on '"Schubert, Erin K."'

3. Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate–Ribose) Polymerase-1–Targeted 18F-Fluorthanatrace PET in Breast Cancer.

Author

Young, Anthony J., Pantel, Austin R., Kiani, Mahsa, Doot, Robert K., Bagheri, Sina, Pryma, Daniel A., Farwell, Michael D., Li, Shihong, Lee, Hsiaoju, Schubert, Erin K., Secreto, Anthony, Zuckerman, Samantha P., Nayak, Anupma, Choi, Hoon, Carlin, Sean, DeMichele, Angela, Mankoff, David A., Zhou, Rong, Mach, Robert H., and McDonald, Elizabeth S.

Published
2024
Full Text
View/download PDF

4. Biodistribution, dosimetry, and temporal signal-to-noise ratio analyses of normal and cancer uptake of [68Ga]Ga-P15-041, a gallium-68 labeled bisphosphonate, from first-in-human studies

Author

Doot, Robert K., Young, Anthony J., Daube-Witherspoon, Margaret E., Alexoff, David, Labban, Kyle J., Lee, Hwan, Wu, Zehui, Zha, Zhihao, Choi, Seok R., Ploessl, Karl H., Schubert, Erin K., Lee, Hsiaoju, Zhu, Lin, Reddin, Janet S., Karp, Joel S., Kung, Hank, and Pryma, Daniel A.

Published
2020
Full Text
View/download PDF

6. Data from Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer

Author

Linden, Hannah M., primary, Kurland, Brenda F., primary, Peterson, Lanell M., primary, Schubert, Erin K., primary, Gralow, Julie R., primary, Specht, Jennifer M., primary, Ellis, Georgiana K., primary, Lawton, Thomas J., primary, Livingston, Robert B., primary, Petra, Philip H., primary, Link, Jeanne M., primary, Krohn, Kenneth A., primary, and Mankoff, David A., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Legend from Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer

Author

Linden, Hannah M., primary, Kurland, Brenda F., primary, Peterson, Lanell M., primary, Schubert, Erin K., primary, Gralow, Julie R., primary, Specht, Jennifer M., primary, Ellis, Georgiana K., primary, Lawton, Thomas J., primary, Livingston, Robert B., primary, Petra, Philip H., primary, Link, Jeanne M., primary, Krohn, Kenneth A., primary, and Mankoff, David A., primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure 1A-B from Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer

Author

Linden, Hannah M., primary, Kurland, Brenda F., primary, Peterson, Lanell M., primary, Schubert, Erin K., primary, Gralow, Julie R., primary, Specht, Jennifer M., primary, Ellis, Georgiana K., primary, Lawton, Thomas J., primary, Livingston, Robert B., primary, Petra, Philip H., primary, Link, Jeanne M., primary, Krohn, Kenneth A., primary, and Mankoff, David A., primary

Published
2023
Full Text
View/download PDF

12. Potential clinical utility of 68Ga-DOTATATE PET/CT for detection and response assessment in cardiac sarcoidosis.

Author

Lee, Hwan, Schubert, Erin K., Vidula, Mahesh K., Pryma, Daniel A., Marchlinski, Francis E., Goldberg, Lee R., Clancy, Caitlin B., Rossman, Milton D., DiCarli, Marcelo F., and Bravo, Paco E.

Abstract

Background: Somatostatin receptor is expressed in sarcoid granulomas, and preliminary clinical studies have shown that myocardial sarcoidosis can be identified on somatostatin receptor-targeted PET. We examined the potential clinical use of 68Ga-DOTATATE PET/CT for diagnosis and response assessment in cardiac sarcoidosis compared to 18F-FDG PET/CT. Methods: Eleven cardiac sarcoidosis patients with 18F-FDG PET/CT were prospectively enrolled for cardiac 68Ga-DOTATATE PET/CT. The two PET/CT studies were interpreted independently and were compared for patient-level and segment-level concordance, as well as for the degree of radiotracer uptake. Follow-up 68Ga-DOTATATE PET/CT was performed in eight patients. Results: Patient-level concordance was 91%: ten patients had multifocal DOTATATE uptake (active cardiac sarcoidosis) and one patient showed diffuse DOTATATE uptake. Segment-level agreement was 77.1% (Kappa 0.53 ± 0.07). The SUVmax-to-blood pool ratio was lower on 68Ga-DOTATATE PET/CT (3.2 ± 0.6 vs. 4.9 ± 1.5, P = 0.006 on paired t test). Follow-up 68Ga-DOTATATE PET/CT showed one case of complete response and one case of partial response, while 18F-FDG PET/CT showed four cases of response, including three with complete response. Conclusion: Compared to 18F-FDG PET/CT, 68Ga-DOTATATE PET/CT can identify active cardiac sarcoidosis with high patient-level concordance, but with moderate segment-level concordance, low signal-to-background ratio, and underestimation of treatment response. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

19. Preliminary Evaluation of 68Ga-P16-093, a PET Radiotracer Targeting Prostate-Specific Membrane Antigen in Prostate Cancer.

Author

Lee, Hwan, Scheuermann, Joshua S., Young, Anthony J., Doot, Robert K., Daube-Witherspoon, Margaret E., Schubert, Erin K., Fillare, Matthew A., Alexoff, David, Karp, Joel S., Kung, Hank F., and Pryma, Daniel A.

Subjects
PROSTATE cancer, PET (Computer), POSITRON emission tomography, COMPUTED tomography, BLADDER
Abstract

Purpose: Prostate-specific membrane antigen (PSMA) is a promising molecular target for imaging of prostate adenocarcinoma. 68Ga-P16-093, a small molecule PSMA ligand, previously showed equivalent diagnostic performance compared to 68Ga-PSMA-11 PET/CT in a pilot study of prostate cancer patients with biochemical recurrence (BCR). We performed a pilot study for further characterization of 68Ga-P16-093 including comparison to conventional imaging.Procedures: Patients were enrolled into two cohorts. The biodistribution cohort included 8 treated prostate cancer patients without recurrence, who underwent 6 whole body PET/CT scans with urine sampling for dosimetry using OLINDA/EXM. The dynamic cohort included 15 patients with BCR and 2 patients with primary prostate cancer. Two patients with renal cell carcinoma were also enrolled for exploratory use. A dynamic PET/CT was followed by 2 whole body scans for imaging protocol optimization based on bootstrapped replicates. 68Ga-P16-093 PET/CT was compared for diagnostic performance against available 18F-fluciclovine PET/CT, 99mTc-MDP scintigraphy, diagnostic CT, and MRI.Results: 68Ga-P16-093 deposited similar effective dose (0.024 mSv/MBq) and lower urinary bladder dose (0.064 mSv/MBq) compared to 68Ga-PSMA-11. The kidneys were the critical organ (0.290 mSv/MBq). While higher injected activities were preferable, lower injected activities at 74-111 MBq (2-3 mCi) yielded 80% retention in signal-to-noise ratio. The optimal injection-to-scan interval was 60 min, with acceptable delay up to 90 min. 68Ga-P16-093 PET/CT showed superior diagnostic performance over conventional imaging with overall patient-level lesion detection rate of 71%, leading to a change in management in 42% of the patients.Conclusions: Based on its favorable imaging characteristics and diagnostic performance in prostate cancer, 68Ga-P16-093 PET/CT merits further investigation in larger clinical studies. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

22. Kinetic and Static Analysis of Poly-(Adenosine Diphosphate-Ribose) Polymerase-1–Targeted 18F-Fluorthanatrace PET Images of Ovarian Cancer

Author

Young, Anthony J., primary, Pantel, Austin R., additional, Viswanath, Varsha, additional, Dominguez, Tiffany L., additional, Makvandi, Mehran, additional, Lee, Hsiaoju, additional, Li, Shihong, additional, Schubert, Erin K., additional, Pryma, Daniel A., additional, Farwell, Michael D., additional, Mach, Robert H., additional, Simpkins, Fiona, additional, Lin, Lilie L., additional, Mankoff, David A., additional, and Doot, Robert K., additional

Published
2021
Full Text
View/download PDF

25. 18F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2− Metastatic Breast Cancer

Author

Peterson, Lanell M., primary, Kurland, Brenda F., additional, Yan, Fengting, additional, Jiresova, Alena Novakova-, additional, Gadi, Vijayakrishna K., additional, Specht, Jennifer M., additional, Gralow, Julie R., additional, Schubert, Erin K., additional, Link, Jeanne M., additional, Krohn, Kenneth A., additional, Eary, Janet F., additional, Mankoff, David A., additional, and Linden, Hannah M., additional

Published
2020
Full Text
View/download PDF

32. Breast Cancer 18F-ISO-1 Uptake as a Marker of Proliferation Status

Author

McDonald, Elizabeth S., primary, Doot, Robert K., additional, Young, Anthony J., additional, Schubert, Erin K., additional, Tchou, Julia, additional, Pryma, Daniel A., additional, Farwell, Michael D., additional, Nayak, Anupma, additional, Ziober, Amy, additional, Feldman, Michael D., additional, DeMichele, Angela, additional, Clark, Amy S., additional, Shah, Payal D., additional, Lee, Hsiaoju, additional, Carlin, Sean D., additional, Mach, Robert H., additional, and Mankoff, David A., additional

Published
2019
Full Text
View/download PDF

33. PennPET Explorer: Human Imaging on a Whole-Body Imager

Author

Pantel, Austin R., primary, Viswanath, Varsha, additional, Daube-Witherspoon, Margaret E., additional, Dubroff, Jacob G., additional, Muehllehner, Gerd, additional, Parma, Michael J., additional, Pryma, Daniel A., additional, Schubert, Erin K., additional, Mankoff, David A., additional, and Karp, Joel S., additional

Published
2019
Full Text
View/download PDF

38. Correction to: a Phase 2 Study of 16α-[18F]-Fluoro-17β-Estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)

Author

Peterson, Lanell M., primary, Kurland, Brenda F., additional, Schubert, Erin K., additional, Link, Jeanne M., additional, Gadi, V. K., additional, Specht, Jennifer M., additional, Eary, Janet F., additional, Porter, Peggy, additional, Shankar, Lalitha K., additional, Mankoff, David A., additional, and Linden, Hannah M., additional

Published
2018
Full Text
View/download PDF

41. Breast Cancer 18F-ISO-1 Uptake as a Marker of Proliferation Status.

Author

McDonald, Elizabeth S., Doot, Robert K., Young, Anthony J., Schubert, Erin K., Tchou, Julia, Pryma, Daniel A., Farwell, Michael D., Nayak, Anupma, Ziober, Amy, Feldman, Michael D., DeMichele, Angela, Clark, Amy S., Shah, Payal D., Lee, Hsiaoju, Carlin, Sean D., Mach, Robert H., and Mankoff, David A.

Published
2019
Full Text
View/download PDF

43. Use of serial 18F-Fluorothymidine (FLT) PET and Ki-67 to predict response to aromatase inhibitors (AI) in women with ER+ breast cancer.

Author

Roberts, Toni Kay, primary, Peterson, Lanell, additional, Kurland, Brenda, additional, Novakova, Alena, additional, Shields, Andrew, additional, Doot, Robert K, additional, Schubert, Erin K, additional, Gadi, Vijayakrishna K., additional, Specht, Jennifer M., additional, Gralow, Julie, additional, Eary, Janet F., additional, Muzi, Mark, additional, Link, Jeanne, additional, Krohn, Kenneth A., additional, Mankoff, David A., additional, and Linden, Hannah M., additional

Published
2016
Full Text
View/download PDF

44. Serial FDG-PET to predict response, time to skeletal related events, and survival in patients with bone-dominant metastatic breast cancer.

Author

Specht, Jennifer M., primary, Peterson, Lanell, additional, Novakova, Alena, additional, O'Sullivan, Janet N, additional, O'Sullivan, Finbarr, additional, Shields, Andrew, additional, Montgomery, Susan, additional, Linden, Hannah M., additional, Gralow, Julie, additional, Ellis, Georgiana Kehr, additional, Gadi, Vijayakrishna K., additional, Barlow, William E., additional, Doot, Robert K, additional, Schubert, Erin K, additional, Dunnwald, Lisa K, additional, MacDonald, Lawrence, additional, Kinahan, Paul, additional, and Mankoff, David A., additional

Published
2016
Full Text
View/download PDF

46. A phase II clinical trial of HDACi (vorinostat) and AI therapy in breast cancer with molecular imaging correlates.

Author

Linden, Hannah M., primary, Kurland, Brenda F., additional, Link, Jeanne, additional, Novakova, Alena, additional, Chai, Xiaoyu, additional, Specht, Jennifer M., additional, Gadi, Vijayakrishna K., additional, Gralow, Julie, additional, Schubert, Erin K, additional, Peterson, Lanell, additional, Eary, Janet F., additional, Shields, Andrew, additional, Mankoff, David A., additional, and Krohn, Kenneth A., additional

Published
2014
Full Text
View/download PDF

47. A Phase 2 Study of 16α-[18F]-fluoro-17β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)

Author

Peterson, Lanell M., primary, Kurland, Brenda F., additional, Schubert, Erin K., additional, Link, Jeanne M., additional, Gadi, V.K., additional, Specht, Jennifer M., additional, Eary, Janet F., additional, Porter, Peggy, additional, Shankar, Lalitha K., additional, Mankoff, David A., additional, and Linden, Hannah M., additional

Published
2013
Full Text
View/download PDF

49. Vorinostat to restore sensitivity to aromatase inhibitor therapy in metastatic breast cancer: A phase II clinical trial with ER imaging correlates.

Author

Linden, Hannah M., primary, Kurland, Brenda F, additional, Link, Jeanne, additional, Gadi, Vijayakrishna K., additional, Specht, Jennifer M., additional, Gralow, Julie, additional, Schubert, Erin K, additional, Peterson, Lanell, additional, Eary, Janet F., additional, and Mankoff, David A., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results